Hot Stocks Earnings Forecast: General Motors, Petroleo Brasileiro Petrobras S.A., Oncothyreon, Regions Financial, Delta Air Lines, and Exxon Mobil

Dec 20, 2012, 09:00 ET from

VANCOUVER, British Columbia, Dec. 20, 2012 /PRNewswire/ -- has issued consensus earnings forecast reports and equity research for the following companies: General Motors (NYSE: GM), Petroleo Brasileiro Petrobras S.A. (NYSE: PBR), Oncothyreon (NASDAQ: ONTY), Regions Financial (NYSE: RF), Delta Air Lines (NYSE: DAL), and Exxon Mobil (NYSE: XOM).

(Logo: )

(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)

Report Highlights:

General Motors Company (NYSE: GM): On December 18, General Motors Company (NYSE: GM) announced the appointment of Norman H. Wesley as Chairman of the Board of Directors. Moreover, A.D. "David" Mackay has been named as independent Director, which expands the company's Board of Directors to ten members. What's more, Michael J. Mardy, previously interim Chairman of the Board, will return to his role as Audit Committee Chair, effective December 12, 2012. See GM earnings forecast report here.

Read Full Report:

Petroleo Brasileiro Petrobras S.A. (ADR) (NYSE: PBR): Petroleo Brasileiro Petrobras S.A. (ADR) (NYSE: PBR) announced that it has signed an agreement to acquire a 100% stake in Araucaria Nitrogenados SA from Vale SA, in exchange of US$234 million. The stock rose US$0.65 (or 3.33%) to US$20.18 with more than 27.41 million shares traded hands, compared to its average volume of 14.09 million shares. Investors may want to find out where PBR will go from here. Observe comprehensive Petroleo Brasileiro Petrobras S.A. earnings forecast report here.

Read Full Report:

Oncothyreon Inc. (USA) (NASDAQ: ONTY): At the close of the trading day, shares of Oncothyreon Inc. (USA) (NASDAQ: ONTY) plunged 51.33% to US$2.19 and hit a new 52-week low of US$1.71. Abnormal trading volume of Oncothyreon was found reaching 32.74 million shares, 43 times heavier than usual day trading. This is after the drug developer announced that the pivotal Phase 3 clinical trial of L-BLP25, known as START, failed to meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell lung cancer. Check ONTY earnings forecast report below.

Read Full Report:

Today also observed abnormal trade volume for the following companies; Check out the consensus earnings forecast reports below:

Regions Financial Corporation (NYSE: RF):

Read Full Report:

Delta Air Lines, Inc. (NYSE: DAL):

Read Full Report:

Exxon Mobil Corporation (NYSE: XOM):

Read Full Report:

About focuses on tracking and monitoring company Earnings Data for top market movers in US stocks market. features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.

Important Disclaimer:
Please visit: for details.